Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening

1990 • 9,412 citations

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma

1998 • 1,852 citations

In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain

1977 • 1,743 citations

MISMATCH REPAIR IN REPLICATION FIDELITY, GENETIC RECOMBINATION, AND CANCER BIOLOGY

1996 • 1,485 citations

Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

1997 • 872 citations

Temozolomide and treatment of malignant glioma.

2000 • 695 citations

Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.

1994 • 506 citations

Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

2000 • 487 citations

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

2004 • 476 citations

NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA

1994 • 417 citations

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

1998 • 413 citations

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

1987 • 386 citations

DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines

1998 • 350 citations

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents

1997 • 248 citations

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

1996 • 236 citations

Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.

1996 • 218 citations

O6-benzylguanine and its role in chemotherapy.

1997 • 214 citations

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

2000 • 201 citations

Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.

1999 • 160 citations

DNA crosslinking induced by X-rays and chemical agents

1977 • 157 citations

Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors

2002 • 151 citations

Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors

2002 • 143 citations

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

2001 • 139 citations

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors

1995 • 131 citations

A Chemical and Genetic Approach Together Define the Biological Consequences of 3-Methyladenine Lesions in the Mammalian Genome

1998 • 126 citations

Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes

1999 • 98 citations

Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitro

1996 • 98 citations

Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival

2000 • 95 citations

[19] Tissue NAD as a biochemical measure of niacin status in humans

1997 • 92 citations

O6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

1998 • 88 citations

Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen

2000 • 87 citations

Review of mammalian DNA repair and translational implications.

2000 • 75 citations

The impact of p53 status on cellular sensitivity to antifolate drugs.

2001 • 74 citations

O 6-Benzylguanine Potentiates the In Vivo Toxicity and Clastogenicity of Temozolomide and BCNU in Mouse Bone Marrow

1997 • 59 citations

Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds

1999 • 58 citations

Disturbances in DNA precursor metabolism associated with exposure to an inhibitor of poly(ADP-ribose) synthetase

1986 • 49 citations

Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.

1999 • 47 citations

Direct assay for O6-methylguanine-DNA methyltransferase and comparison of detection methods for the methylated enzyme in polyacrylamide gels and electroblots

1991 • 16 citations

Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells

2000 • 15 citations

Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamide.

1990 • 13 citations

Mismatch repair and drug responses in cancer

1999 • 8 citations